European Commission (EC) Extends Approval of Evkeeza: Children Young 6-months Old with HoFH
January 6, 2025
Ultragenyx Pharmaceutical, a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and ultrarare genetic diseases, announced that the European Commission